231 related articles for article (PubMed ID: 23028593)
1. The dual orexin/hypocretin receptor antagonist, almorexant, in the ventral tegmental area attenuates ethanol self-administration.
Srinivasan S; Simms JA; Nielsen CK; Lieske SP; Bito-Onon JJ; Yi H; Hopf FW; Bonci A; Bartlett SE
PLoS One; 2012; 7(9):e44726. PubMed ID: 23028593
[TBL] [Abstract][Full Text] [Related]
2. Biochemical and electrophysiological characterization of almorexant, a dual orexin 1 receptor (OX1)/orexin 2 receptor (OX2) antagonist: comparison with selective OX1 and OX2 antagonists.
Malherbe P; Borroni E; Pinard E; Wettstein JG; Knoflach F
Mol Pharmacol; 2009 Sep; 76(3):618-31. PubMed ID: 19542319
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of the dual orexin receptor antagonist almorexant and the GABA(A)-α1 receptor modulator zolpidem, alone or combined with ethanol, on motor performance in the rat.
Steiner MA; Lecourt H; Strasser DS; Brisbare-Roch C; Jenck F
Neuropsychopharmacology; 2011 Mar; 36(4):848-56. PubMed ID: 21150905
[TBL] [Abstract][Full Text] [Related]
4. The dual orexin receptor antagonist almorexant induces sleep and decreases orexin-induced locomotion by blocking orexin 2 receptors.
Mang GM; Dürst T; Bürki H; Imobersteg S; Abramowski D; Schuepbach E; Hoyer D; Fendt M; Gee CE
Sleep; 2012 Dec; 35(12):1625-35. PubMed ID: 23204605
[TBL] [Abstract][Full Text] [Related]
5. Inhibition of orexin-1/hypocretin-1 receptors inhibits yohimbine-induced reinstatement of ethanol and sucrose seeking in Long-Evans rats.
Richards JK; Simms JA; Steensland P; Taha SA; Borgland SL; Bonci A; Bartlett SE
Psychopharmacology (Berl); 2008 Jul; 199(1):109-17. PubMed ID: 18470506
[TBL] [Abstract][Full Text] [Related]
6. Intact learning and memory in rats following treatment with the dual orexin receptor antagonist almorexant.
Dietrich H; Jenck F
Psychopharmacology (Berl); 2010 Oct; 212(2):145-54. PubMed ID: 20631993
[TBL] [Abstract][Full Text] [Related]
7. Antagonism of rat orexin receptors by almorexant attenuates central chemoreception in wakefulness in the active period of the diurnal cycle.
Li A; Nattie E
J Physiol; 2010 Aug; 588(Pt 15):2935-44. PubMed ID: 20547681
[TBL] [Abstract][Full Text] [Related]
8. Nicotine self-administration in the rat: effects of hypocretin antagonists and changes in hypocretin mRNA.
LeSage MG; Perry JL; Kotz CM; Shelley D; Corrigall WA
Psychopharmacology (Berl); 2010 Apr; 209(2):203-12. PubMed ID: 20177882
[TBL] [Abstract][Full Text] [Related]
9. Blockade of orexin receptors with Almorexant reduces cardiorespiratory responses evoked from the hypothalamus but not baro- or chemoreceptor reflex responses.
Iigaya K; Horiuchi J; McDowall LM; Lam AC; Sediqi Y; Polson JW; Carrive P; Dampney RA
Am J Physiol Regul Integr Comp Physiol; 2012 Nov; 303(10):R1011-22. PubMed ID: 23019212
[TBL] [Abstract][Full Text] [Related]
10. The brain orexin system and almorexant in fear-conditioned startle reactions in the rat.
Steiner MA; Lecourt H; Jenck F
Psychopharmacology (Berl); 2012 Oct; 223(4):465-75. PubMed ID: 22592903
[TBL] [Abstract][Full Text] [Related]
11. Almorexant, a dual orexin receptor antagonist for the treatment of insomnia.
Neubauer DN
Curr Opin Investig Drugs; 2010 Jan; 11(1):101-10. PubMed ID: 20047164
[TBL] [Abstract][Full Text] [Related]
12. Orexin receptor antagonism prevents transcriptional and behavioral plasticity resulting from stimulant exposure.
Winrow CJ; Tanis KQ; Reiss DR; Rigby AM; Uslaner JM; Uebele VN; Doran SM; Fox SV; Garson SL; Gotter AL; Levine DM; Roecker AJ; Coleman PJ; Koblan KS; Renger JJ
Neuropharmacology; 2010 Jan; 58(1):185-94. PubMed ID: 19596018
[TBL] [Abstract][Full Text] [Related]
13. Chemical stimulation of the lateral hypothalamus induces conditioned place preference in rats: Involvement of OX1 and CB1 receptors in the ventral tegmental area.
Taslimi Z; Haghparast A; Hassanpour-Ezatti M; Safari MS
Behav Brain Res; 2011 Feb; 217(1):41-6. PubMed ID: 20937330
[TBL] [Abstract][Full Text] [Related]
14. Central orexin (hypocretin) 2 receptor antagonism reduces ethanol self-administration, but not cue-conditioned ethanol-seeking, in ethanol-preferring rats.
Brown RM; Khoo SY; Lawrence AJ
Int J Neuropsychopharmacol; 2013 Oct; 16(9):2067-79. PubMed ID: 23601187
[TBL] [Abstract][Full Text] [Related]
15. Neurogenesis-independent antidepressant-like effects on behavior and stress axis response of a dual orexin receptor antagonist in a rodent model of depression.
Nollet M; Gaillard P; Tanti A; Girault V; Belzung C; Leman S
Neuropsychopharmacology; 2012 Sep; 37(10):2210-21. PubMed ID: 22713907
[TBL] [Abstract][Full Text] [Related]
16. Chemical stimulation of the lateral hypothalamus induced seeking behaviors in rats: Involvement of orexin receptors in the ventral tegmental area.
Mahmoudi M; Maleki-Roveshti M; Karimi-Haghighi S; Haghparast A
Eur J Pharmacol; 2020 Nov; 886():173433. PubMed ID: 32763297
[TBL] [Abstract][Full Text] [Related]
17. Elucidation of the metabolic pathways and the resulting multiple metabolites of almorexant, a dual orexin receptor antagonist, in humans.
Dingemanse J; Hoever P; Hoch M; Treiber A; Wagner-Redeker W; Miraval T; Hopfgartner G; Shakeri-Nejad K
Drug Metab Dispos; 2013 May; 41(5):1046-59. PubMed ID: 23431113
[TBL] [Abstract][Full Text] [Related]
18. Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat.
Dugovic C; Shelton JE; Aluisio LE; Fraser IC; Jiang X; Sutton SW; Bonaventure P; Yun S; Li X; Lord B; Dvorak CA; Carruthers NI; Lovenberg TW
J Pharmacol Exp Ther; 2009 Jul; 330(1):142-51. PubMed ID: 19363060
[TBL] [Abstract][Full Text] [Related]
19. Orexin-1 receptor signalling within the ventral tegmental area, but not the paraventricular thalamus, is critical to regulating cue-induced reinstatement of cocaine-seeking.
James MH; Charnley JL; Levi EM; Jones E; Yeoh JW; Smith DW; Dayas CV
Int J Neuropsychopharmacol; 2011 Jun; 14(5):684-90. PubMed ID: 21447232
[TBL] [Abstract][Full Text] [Related]
20. Dual orexin receptor antagonism by almorexant does not potentiate impairing effects of alcohol in humans.
Hoch M; Hay JL; Hoever P; de Kam ML; te Beek ET; van Gerven JM; Dingemanse J
Eur Neuropsychopharmacol; 2013 Feb; 23(2):107-17. PubMed ID: 22658401
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
